Somewhat Favorable News Coverage Somewhat Unlikely to Affect Alimera Sciences (ALIM) Stock Price
News headlines about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive on Monday, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.6335064670026 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s analysis:
- Global Diabetic Retinopathy Market Anticipated Growth By Increasing Incidence of Ophthalmic Complications in Diabetic Patients (marketwatch.com)
- Identify Buy Sell Signals using Technical Indicators of Alimera Sciences, Inc. (ALIM) – Wall Street Morning (wallstreetmorning.com)
- Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Alimera Sciences (ALIM) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS (americanbankingnews.com)
Alimera Sciences (NASDAQ:ALIM) traded down $0.02 during mid-day trading on Monday, hitting $1.19. 29,779 shares of the company’s stock traded hands, compared to its average volume of 149,886. The stock has a market capitalization of $84.68, a P/E ratio of -3.69 and a beta of 1.58. Alimera Sciences has a 52-week low of $1.03 and a 52-week high of $1.72. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65.
A number of equities research analysts recently weighed in on ALIM shares. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Alimera Sciences in a research note on Monday, January 22nd. Zacks Investment Research downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Monday, November 27th. Finally, ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research note on Monday, November 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $3.38.
In other Alimera Sciences news, SVP Philip Ashman sold 25,500 shares of Alimera Sciences stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $30,600.00. Following the transaction, the senior vice president now directly owns 12,750 shares of the company’s stock, valued at $15,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO C. Daniel Myers sold 52,900 shares of Alimera Sciences stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total transaction of $65,067.00. Following the transaction, the chief executive officer now directly owns 154,411 shares in the company, valued at $189,925.53. The disclosure for this sale can be found here. Insiders have sold 184,704 shares of company stock worth $224,432 over the last three months. Insiders own 14.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/03/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-alimera-sciences-alim-stock-price.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.